Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is Pinealon? Structure, Sequence, and Research

Schematic of the Pinealon sequence Glu-Asp-Arg and its one-letter abbreviation EDR.

Pinealon is a synthetic tripeptide—a peptide containing three amino-acid residues—with the sequence Glu-Asp-Arg, abbreviated EDR. Published research has examined its relationship to oxidative-stress responses, cell viability, signaling and cell-cycle behavior.[1] Understanding this compound means separating what each experiment measured from the broader mechanisms proposed to explain it. For laboratory procurement context only, SaiyanMed lists a Pinealon research peptide product page; that page is not independent verification of any cited study material.

Pinealon Structure and Sequence

The name Glu-Asp-Arg describes the amino-acid residue order. EDR expresses that same sequence using one-letter codes. The 2011 cell-study abstract identifies Pinealon as this synthetic tripeptide.[1]

Position in sequence Three-letter code Amino acid One-letter code
First Glu Glutamic acid E
Second Asp Aspartic acid D
Third Arg Arginine R

This identifies the sequence discussed in the literature. It does not establish a particular material’s salt form, peptide content, purity or batch composition. Those are separate analytical questions; the studies below do not characterize a SaiyanMed batch.

What Pinealon Cell Studies Have Measured

Cell-study diagram separating ROS, viability, ERK1/2 timing and cell-cycle readouts.

The 2011 abstract describes experiments involving cerebellar granule cells, neutrophils and PC12 cells under oxidative stress. It reports restricted accumulation of reactive oxygen species (ROS), decreased propidium-iodide-measured necrotic cell death, delayed ERK1/2 activation and changes in the cell cycle.[1]

These readouts address different questions. ROS measurements concern the experimental oxidative response; propidium iodide provides a cell-death endpoint. ERK1/2 timing and cell-cycle measurements concern signaling and proliferation. The abstract describes different concentration-response patterns for these outcomes, which the authors used to propose interaction with the cell genome. Those endpoints alone do not demonstrate that interaction. This account uses the abstract, rather than a review of the full methods.[1]

A 2008 English abstract provides a useful contrast. Its experiments included Pinealon and three other peptides. It reports no direct antioxidant activity, while describing effects on lipid peroxidation, stationary intracellular ROS and cell viability. Because the abstract summarizes several peptides, every reported effect cannot be assigned specifically to Pinealon.[2]

The distinction matters: a cellular ROS response and direct chemical antioxidant activity are different experimental questions. Taken together, these abstracts support attention to the model and assay rather than a blanket description of Pinealon as a free-radical scavenger.[1][2]

What the Rat Study Adds

Separate panels showing a Morris water-maze assessment and isolated-cell DCF fluorescence and propidium iodide readouts.

The 2012 full paper investigated offspring in a Wistar rat model of prenatal hyperhomocysteinemia, an experimental condition involving elevated homocysteine. It combined Morris water-maze behavioral assessment with measurements in isolated cerebellar neurons. The paper reports 23 offspring per behavioral group.[3]

Measurement Reported result What it establishes within this study
Offspring homocysteine, Table 2 Remained elevated in the methionine-plus-Pinealon group. The reported findings did not require observed normalization of homocysteine.
DCF fluorescence after challenge, Table 3 Methionine: 158.7 ± 3.8 arbitrary units; methionine plus Pinealon: 108.6 ± 4.1. A lower ROS-related fluorescence readout in the latter group under the assay conditions.
Propidium-iodide-positive cells, Table 3 Methionine: 17.7 ± 2.1%; methionine plus Pinealon: 7.0 ± 0.9%. A difference in a separate cellular damage endpoint.
Water-maze platform search Group differences disappeared by the fifth trial. The behavioral difference did not persist across every trial.

These observations come from the 2012 paper; the numerical uncertainties shown are standard deviations.[3]

A worked reading: Table 2 leaves homocysteine elevated, while Table 3 shows lower DCF fluorescence and fewer propidium-iodide-positive cells in the Pinealon-associated group than in the methionine group. Together, these findings describe altered cellular responses despite persistent elevation of the measured homocysteine. They do not identify the molecular cause, and fluorescence units should not be converted into a percentage of clinical benefit.[3]

The prenatal design also makes the experimental unit important: offspring from the same family or litter should not automatically be treated as independent prenatal exposures. That consideration, together with the trial-dependent behavioral findings, limits broad interpretation of the offspring count and maze results.

What Is Known About Pinealon’s Mechanism?

Mechanistic research extends beyond the ROS and viability experiments. A separate 2011 study examined fluorescence-labeled short peptides in HeLa cells and interactions between intact peptides and nucleic acids in cell-free assays. Its abstract explicitly includes Pinealon, identified as Glu-Asp-Arg.[4]

In the localization experiments, the researchers observed fluorescence in the cytoplasm, nucleus and nucleolus after incubation with fluorescein-isothiocyanate-labeled peptides, including Pinealon. This supplies evidence about the location of a tagged-peptide-associated fluorescent signal in that cell model. It should be distinguished from demonstrating the distribution of unmodified Pinealon in neurons.[4]

In separate experiments, intact peptides affected fluorescence from labeled deoxyribooligonucleotides and DNA–ethidium bromide complexes. The authors interpreted the quenching results as sequence-dependent interactions with nucleic-acid structures. Pinealon was among the peptides reported to prefer CNG-containing oligonucleotides and appeared to prefer CAG-containing sequences.[4]

These are experimental observations relevant to a nucleic-acid interaction hypothesis, rather than an inference drawn only from ROS. Their scope remains specific: tagged-peptide localization in a cancer-cell line and intact-peptide fluorescence assays outside cells. They do not establish neuronal target engagement, brain delivery or functional epigenetic reprogramming. The authors propose possible epigenetic control; only the abstract was reviewed here.[4]

The useful mechanistic question is therefore how these interaction findings connect, if at all, to the signaling, cell-cycle and stress-response observations in other models.

Pinealon Research: Key Questions Still Open

The literature reviewed here offers several complementary research approaches: cellular stress and viability assays, animal behavior, isolated-neuron measurements, tagged-peptide localization and cell-free interaction experiments. It comprises three abstracts and one full animal-model paper, rather than a systematic review of all Pinealon research.

Three questions would help connect these findings:

  • Do the results replicate independently? Replication with clear biological replication and appropriate treatment of litter effects would clarify consistency.
  • Does localization translate into functional interaction? Establishing a relevant interaction for unmodified Pinealon in an appropriate cell model would help connect the separate experimental approaches.
  • Which interaction explains which outcome? Experiments linking a defined molecular interaction to downstream signaling or stress responses would strengthen causal interpretation.

For readers asking what Pinealon is, the sequence provides a clear starting point. The research then becomes a set of model-specific observations and testable mechanisms. The studies discussed here do not establish human therapeutic, cognitive-enhancement or anti-aging benefits. For a broader class overview, see peptide bioregulators: Pinealon, Epithalon, and Cartalax explained.

Frequently Asked Questions

What is the Pinealon sequence?

Pinealon is described as the synthetic tripeptide Glu-Asp-Arg (EDR). Sequence naming identifies the residue order discussed in the literature; it does not certify a commercial batch’s salt form, peptide content, or purity.

What experimental systems appear in Pinealon papers?

Published work spans cell viability and oxidative-stress readouts, rat-model observations, and studies of tagged-peptide localization or nucleic-acid interactions. Each system supports only the endpoint it measured.

Is Pinealon the same as Epithalon or Cartalax?

No. They are different short peptides often grouped under “bioregulator” discussions. Class labels do not make mechanisms interchangeable—see the bioregulators overview.

What does “research use only” mean here?

Related research: What Are Peptide Bioregulators? Pinealon, Epithalon, and Cartalax Explained; Pinealon.

This article is for laboratory and analytical education. It is not medical advice and provides no administration instructions for humans or animals.

Research Use Only Disclaimer

This article is for laboratory and analytical research education only. It is not a validated experimental protocol or medical or veterinary advice. It provides no administration guidance; the research materials discussed are not for administration to humans or animals.

References

  1. Khavinson et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes (2011)
  2. Kozina et al. Biological activity of regulatory peptides in model experiments in vitro—English abstract (2008)
  3. Arutjunyan et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia (2012)
  4. Fedoreyeva et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA (2011)